Lysine-specific demethylase 1A (LSD1, also named KDM1A) is a demethylase that can
remove methyl groups from histones H3K4me1/2 and H3K9me1/2. It is aberrantly expressed …

As a flavin adenine dinucleotide (FAD)-dependent monoamine oxidase, lysine specific
demethylase 1 (LSD1/KDM1A) functions as a transcription coactivator or corepressor to …

Pharmacologic inhibition of LSD1 promotes blast cell differentiation in acute myeloid
leukemia (AML) with MLL translocations. The assumption has been that differentiation is …

Targeted therapy for acute myeloid leukemia (AML) is an effective strategy, but currently
there are very limited therapeutic targets for AML treatment. Histone lysine specific …

Lysine-specific demethylase 5A (KDM5A, also named RBP2 or JARID1A) is a demethylase
that can remove methyl groups from histones H3K4me1/2/3. It is aberrantly expressed in …

LSD1 was significantly over-expressed in several cancer types, and its aberrant
overexpression was revealed to play a crucial role in the initiation and progression of …

Lysine-specific demethylase 1 (LSD1/KDM1A) has emerged as a promising therapeutic
target for treating various cancers (such as breast cancer, liver cancer, etc.) and other …

Lysine-specific histone demethylase 1 (LSD-1) is an epigenetic enzyme that oxidatively
cleaves methyl groups from monomethyl and dimethyl Lys4 of histone H3 and is highly …

As one of the crucial targets of epigenetics, histone lysine-specific demethylase 1 (LSD1) is
significant in the occurrence and development of various tumors. Although several …

The pharmacoepigenetic apparatus is integrated by gene clusters of different categories,
including (i) pathogenic genes involved in disease pathogenesis,(ii) mechanistic genes …